Results 81 to 90 of about 51,608 (100)

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Proceedings of the National Academy of Sciences of the United States of America, 2011
F. van Goor, Sabine Hadida, P. Grootenhuis, B. Burton, J. Stack, K. Straley, C. Decker, Mark Miller, Jason Mccartney, E. Olson, J. Wine, R. Frizzell, M. Ashlock, P. Negulescu   +13 more
semanticscholar   +1 more source

Assembly of 809 whole mitochondrial genomes with clinical, imaging, and fluid biomarker phenotyping

Alzheimer's & Dementia, 2018
P. Ridge, Mark E. Wadsworth, Justin B. Miller, A. Saykin, R. Green, J. Kauwe   +5 more
semanticscholar   +1 more source

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation

Thorax, 2011
J. P. Clancy, Steven M. Rowe, F. Accurso, Moira L. Aitken, Raouf S Amin, M. Ashlock, M. Ballmann, Michael P. Boyle, I. Bronsveld, Preston W Campbell, K. De Boeck, Scott H Donaldson, Henry L. Dorkin, J. M. Dunitz, Peter R Durie, M. Jain, A. Leonard, Karen S. McCoy, Richard B. Moss, J. M. Pilewski, D. Rosenbluth, Ronald C. Rubenstein, M. Schechter, M. Botfield, C. Ordoñez, George T Spencer-Green, L. Vernillet, S. Wisseh, Karl Yen, M. Konstan   +29 more
semanticscholar   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Structural Consequences of the 1,2,3‐Triazole as an Amide Bioisostere in Analogues of the Cystic Fibrosis Drugs VX‐809 and VX‐770

ChemMedChem, 2020
Although the 1,2,3‐triazole is a commonly used amide bioisostere in medicinal chemistry, the structural implications of this replacement have not been fully studied.
Jake E. Doiron, C. A. Le, J. Bacsa, G. Breton, K. Martin, S. Aller, M. Turlington   +6 more
semanticscholar   +1 more source

Erratum: “PAPER-64 Constraints on Reionization: The 21 cm Power Spectrum at z = 8.4” (2015, ApJ, 809, 61)

Astrophysical Journal, 2018
z=8.4” (2015, ApJ, 809, 61) Zaki S. Ali, Aaron R. Parsons, Haoxuan Zheng, Jonathan C. Pober, Adrian Liu , James E. Aguirre , Richard F. Bradley, Gianni Bernardi , Chris L. Carilli , Carina Cheng, David R. DeBoer, Matthew R.
Z. Ali, A. Parsons, Haoxuan Zheng, J. Pober, Adrian Liu, J. Aguirre, R. Bradley, G. Bernardi, C. Carilli, Carina Cheng, D. DeBoer, M. Dexter, J. Grobbelaar, J. Horrell, D. Jacobs, P. Klima, D. MacMahon, M. Maree, David F. Moore, N. Razavi, I. Stefan, W. Walbrugh, A. Walker   +22 more
semanticscholar   +1 more source

Effects of Heat Treatments on Mechanical Properties, Specific Wear and Corrosion Rate of HQ 809 Steel for Machinery Components Application

International Conference on Information Control Systems & Technologies, 2018
HQ (High Quality) 809 steel is a HSLA (High Strength Low Alloy) steel and it is equivalent to AISI 4140, JIS SCM440, DIN 42CrMo4. HQ 809 is a chromium molybdenum alloy steel for applications requiring a high tensile strength, good hardenability ...
V. Malau, Wildan Ihsan Fauzi
semanticscholar   +1 more source

BIT^® bioreactor increases in vitro multiplication of quality shoots in sugarcane (Saccharum spp. variety LAICA 04-809)

Plant Cell Tissue and Organ Culture, 2022
Cristofer Orozco-Ortiz, Laura Sánchez, Jorge Araya-Mattey, Isaac Vargas-Solórzano, Emanuel Araya-Valverde   +4 more
semanticscholar   +1 more source

A Randomized Double-Blind Placebo- and Positive-Controlled Crossover Study to Evaluate the Effects of Single Doses of SD-809 (Deutetrabenazine) and Tetrabenazine on the Corrected QT Interval (P2.347)

Neurology, 2016
BACKGROUND: SD-809 (deutetrabenazine) is a VMAT-2 inhibitor in clinical development for treatment of hyperkinetic movement disorders. In a thorough QT (TQT) study, 50 mg of tetrabenazine (TBZ) prolonged the corrected QT (QTc) interval by approximately 8 ...
D. Stamler, E. Offman, M. Bradbury, L. D. Boer   +3 more
semanticscholar   +1 more source

Does Intraprocedural CT Improve the Success Rate of Adrenal Venous Sampling? A Systematic Review and Meta-Analysis of Data from 809 Patients

Cardiovascular and Interventional Radiology, 2021
N. Hafezi-Nejad, D. Gullotti, C. Bailey, M. Lessne, B. Holly   +4 more
semanticscholar   +1 more source

A Relative Bioavailability Study of Three Dose Strengths and Four Dose Levels of SD-809, a Potential Treatment for Movement Disorders (P1.054)

Neurology, 2016
Introduction: SD-809 (deutetrabenazine) is a VMAT-2 inhibitor in clinical development for treatment of hyperkinetic movement disorders. Previous studies have shown that the active metabolites of SD-809, total (α+β)-dihydrodeutetrabenazine (HTBZ), have a ...
D. Stamler, M. Bradbury, L. D. Boer, E. Offman   +3 more
semanticscholar   +1 more source